Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients With Unresectable and Locally-Advanced HCC

Next Previous
Trial Profile

A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients With Unresectable and Locally-Advanced HCC

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment due to inadequate funding. This trial may open as a new clinical trial at a later date, pendingdrug approval.
  • 12 Dec 2022 Planned initiation date changed from 4 Jun 2022 to 10 Dec 2022.
  • 18 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top